Park Place Capital Corp Has $81,000 Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Park Place Capital Corp reduced its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 23.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,096 shares of the pharmaceutical company’s stock after selling 656 shares during the quarter. Park Place Capital Corp’s holdings in GSK were worth $81,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Dorsey & Whitney Trust CO LLC raised its stake in GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after purchasing an additional 278 shares during the last quarter. First PREMIER Bank raised its stake in GSK by 6.5% during the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company’s stock valued at $181,000 after purchasing an additional 286 shares during the last quarter. Northwest Bank & Trust Co raised its stake in GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock valued at $765,000 after purchasing an additional 289 shares during the last quarter. GC Wealth Management RIA LLC raised its stake in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after purchasing an additional 353 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in GSK by 2.1% during the first quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company’s stock worth $713,000 after buying an additional 386 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price target on the stock. Finally, Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $37.38.

GSK Stock Down 0.0%

Shares of NYSE:GSK opened at $38.55 on Friday. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The company’s fifty day moving average is $38.86 and its 200-day moving average is $36.93. The company has a market capitalization of $78.92 billion, a PE ratio of 19.87, a P/E/G ratio of 1.35 and a beta of 0.52.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the previous year, the company earned $0.43 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 annualized dividend and a dividend yield of 4.38%. The ex-dividend date is Friday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 87.11%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.